Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder - Alterity

Alterity Therapeutics advances ATH434 toward Phase 3 after FDA alignment on trial design for MSA, while shares decline in premarket trading.

Raccontata dabenzinga.com